"Intravitreal Injections" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.
| Descriptor ID |
D058449
|
| MeSH Number(s) |
E02.319.267.530.475.500
|
| Concept/Terms |
Intravitreal Injections- Intravitreal Injections
- Injection, Intravitreal
- Injections, Intravitreal
- Intravitreal Injection
|
Below are MeSH descriptors whose meaning is more general than "Intravitreal Injections".
Below are MeSH descriptors whose meaning is more specific than "Intravitreal Injections".
This graph shows the total number of publications written about "Intravitreal Injections" by people in this website by year, and whether "Intravitreal Injections" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 4 | 4 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 5 | 5 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 4 | 4 |
| 2024 | 2 | 3 | 5 |
| 2025 | 0 | 2 | 2 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Intravitreal Injections" by people in Profiles.
-
Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction. JAMA Ophthalmol. 2026 05 01; 144(5):415-422.
-
MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy. Ophthalmologica. 2026; 249(3):265-274.
-
Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial. Ophthalmology. 2026 Apr; 133(4):451-465.
-
IMPACT OF THE DEXAMETHASONE IMPLANT ON SLOWING DIABETIC RETINOPATHY PROGRESSION: Post Hoc Analysis of the MEAD Study. Retina. 2025 12 01; 45(12):2252-2262.
-
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial. Ophthalmology. 2026 May; 133(5):577-588.
-
Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy - a multicentre study. Graefes Arch Clin Exp Ophthalmol. 2026 Feb; 264(2):407-416.
-
Visual outcomes associated with optical coherence tomography biomarkers in diabetic macular edema: A systematic review. Surv Ophthalmol. 2026 Mar-Apr; 71(2):289-308.
-
Predicting treatment response in retinal vein occlusions using baseline optical coherence tomography biomarkers: A systematic review. Surv Ophthalmol. 2026 Jan-Feb; 71(1):100-118.
-
Baseline OCT Biomarkers Predicting Visual Outcomes in Neovascular Age-Related Macular Degeneration: A Meta-Analysis. Ophthalmology. 2025 11; 132(11):1241-1252.
-
Short-term effects of tetracycline use in patients with diabetic retinopathy. Can J Ophthalmol. 2025 12; 60(6):e858-e868.